Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 2Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1Hodgkin Disease 1

Interventions

Peripheral Blood Stem Cell Transplantation 36fludarabine phosphate 33Cyclophosphamide 31Mycophenolic Acid 26Whole-Body Irradiation 23Tacrolimus 22Cyclosporine 19Radiotherapy 16Busulfan 16Antilymphocyte Serum 15Methotrexate 14Filgrastim 12Etoposide 12Flow Cytometry 11Rituximab 8Methylprednisolone 8Melphalan 8Brentuximab Vedotin 8pembrolizumab 7Therapeutics 7Lenalidomide 7Bortezomib 7Psychiatric Rehabilitation 6Gemcitabine 6Cord Blood Stem Cell Transplantation 6Bexarotene 6romidepsin 5mogamulizumab 5fludarabine 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mycosis Fungoides × AFM13 × Clear all
NCT04074746 2025-09-30

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

M.D. Anderson Cancer Center

Phase 1/2 Completed
45 enrolled
Lymphoid

Mycosis Fungoides, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡